Author

O. A. Olaleye

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1

Frequent Co-Authors

C. C. Onyenaka· 2 shared M. Kaur· 2 shared T. O. Adebusuyi· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

3 top collaborators · 3 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

C. C. Onyenaka

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologybioRxivPreprintSep 13, 2020

Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2.

O. A. Olaleye, M. Kaur, C. C. Onyenaka

This study identifies Ambroxol hydrochloride and Bromhexine hydrochloride as inhibitors of the SARS-CoV-2 spike protein RBD interaction with human ACE2, suggesting their potential for repurposing as antiviral drugs.

DOI 10.1101/2020.09.13.295691

humanexperimental assay

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivAug 14, 2020

Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro

O. A. Olaleye, M. Kaur, C. C. Onyenaka, T. O. Adebusuyi

This study identifies Clioquinol and its analogues as potent inhibitors of SARS-CoV-2 infection and ACE2-Spike protein interaction in vitro.

DOI 10.1016/j.heliyon.2021.e06426

experimental assayhost-pathogen & immune response

𝕏 PostBluesky